Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $630.12M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.29M
Average 0.74M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
PTC Therapeutics, Inc. NASDAQ:PTCT | $5.30B | $63.49 | Undervalued | -35.0 | -21.29% |
Ionis Pharmaceuticals, Inc. NASDAQ:IONS | $4.84B | $29.06 | Not rated | -37.5 | -63.81% |
Dyne Therapeutics, Inc. NASDAQ:DYN | $3.22B | $17.16 | Not rated | -7.2 | -23.57% |
Stoke Therapeutics, Inc. NASDAQ:STOK | $1.75B | $26.68 | Undervalued | -11.1 | -8.68% |
Sarepta Therapeutics, Inc. NASDAQ:SRPT | $1.72B | $16.07 | Undervalued | 27.8 | -15.31% |
Solid Biosciences Inc. NASDAQ:SLDB | $763.42M | $6.84 | Not rated | -4.3 | +39.37% |
Wave Life Sciences Ltd. NASDAQ:WVE | $617.33M | $3.13 | Not rated | -6.6 | -60.06% |
Larimar Therapeutics, Inc. NASDAQ:LRMR | $313.73M | $3.02 | Not rated | -1.8 | -11.80% |
PepGen Inc. NASDAQ:PEPG | $301.98M | $4.36 | Not rated | -1.6 | -32.40% |
Fulcrum Therapeutics, Inc. NASDAQ:FULC | $287.64M | $3.77 | Not rated | -3.6 | -61.46% |
Continue the stock analysis
Jump to another research area for this company.